TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

This study is testing a new oral drug called TLN-121 in people with several types of non-Hodgkin lymphoma (a blood cancer) that have come back or stopped responding to prior treatment. The study includes people with certain types of B-cell lymphoma (such as large B-cell lymphoma and follicular lymphoma) and T-cell lymphoma. **You may be eligible if...** - You have confirmed relapsed or refractory non-Hodgkin lymphoma (specific eligible subtypes are listed in the study) - You have received at least 1–2 prior treatments depending on your lymphoma type - You have measurable cancer on imaging and are in good general health (ECOG 0–1) **You may NOT be eligible if...** - Your lymphoma has spread to the brain or spinal cord (CNS involvement) - You have had a stem cell transplant within the past 60–90 days or CAR T-cell therapy within the past 4 weeks - You have a serious medical illness or active uncontrolled infection - You are pregnant or breastfeeding - You have conditions that would prevent you from absorbing the oral medication Talk to your doctor to see if this trial is right for you.